Floatz logo

Cyclophosphamide

Skin Diseases

Eli Lilly and CompanySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Skin Diseases cohort.

Asset / SponsorPhaseRating
Capecitabine
Binghe Xu
Phase 3B
Docetaxel
Binghe Xu
Phase 3B
ABATACEPT RECOMBINANT
Eli Lilly and Company
Phase 2B
Baricitinib
Eli Lilly and Company
Phase 2B
DEXAMETHASONE
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B

View all 13 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →